コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 (10% in the praliciguat group and 11% in the placebo group).
2 ive vitamin D at Month 6 (31% vs. 10% in the placebo group).
3 , respectively (P =.032 for the high-dose vs placebo group).
4 ] in the riluzole group, and 13 [12%] in the placebo group).
5 aths (49 in the cytisine group and 42 in the placebo group).
6 45 in the sotagliflozin group and 355 in the placebo group).
7 group) and nasopharyngitis (17% vs 4% in the placebo group).
8 ab group vs 107 [40%] of 265 patients in the placebo group).
9 umab group, 183 [46%] of 396 patients in the placebo group).
10 gned to the colchicine group and 2760 to the placebo group.
11 % in the vitamin D group versus 73.7% in the placebo group.
12 e group and 282 (51%) of 551 patients in the placebo group.
13 d 12 (75%) occurred among 11 patients in the placebo group.
14 e 10 mg group were significantly higher than placebo group.
15 in the combined tranexamic acid group vs the placebo group.
16 roxaban group, and 3278 were assigned to the placebo group.
17 reduced in the frontal lobe compared to the placebo group.
18 onger in the steroid group compared with the placebo group.
19 assigned, 50 to the rituximab and 47 to the placebo group.
20 1.6% in the LY-CoV555 group and 6.3% in the placebo group.
21 atients in the 300 IR group and 14.9% in the placebo group.
22 D(3) supplementation group, and 1999 to the placebo group.
23 n the combined REGN-COV2 dose groups and the placebo group.
24 s in the evolocumab group versus 7.9% in the placebo group.
25 olimumab group and in 2 (7%) of those in the placebo group.
26 AUC glucose increased significantly in each placebo group.
27 urred in the dexamethasone group than in the placebo group.
28 he venetoclax group and none reported in the placebo group.
29 ed in the pertuzumab group compared with the placebo group.
30 de group and 20 per 100 patient-years in the placebo group.
31 gned to the teprotumumab group and 42 to the placebo group.
32 group and in 79 of 181 patients (44%) in the placebo group.
33 ommon in the difelikefalin group than in the placebo group.
34 gned to the intervention group and 52 to the placebo group.
35 e aldafermin group and 4% of patients in the placebo group.
36 and 31.3% +/- 22% and 25.2% +/- 17.2% in the placebo group.
37 ive and in 10.4% (21/202) of children in the placebo group.
38 e azithromycin group and 90.4% (10.1) in the placebo group.
39 and 4 (25%) occurred among 3 patients in the placebo group.
40 ned to the luspatercept group and 112 to the placebo group.
41 211 in the vitamin D(3) group and 204 in the placebo group.
42 d tics (d = 1.30, p < 0.001) relative to the placebo group.
43 le recurrences in the same individual in the placebo group.
44 n the combined REGN-COV2 dose groups and the placebo group.
45 h vaccine group and two to the corresponding placebo group.
46 probiotic group and 32 of the events in the placebo group.
47 mes more likely to achieve the MCID than the placebo group.
48 mide group and 77% (95% CI, 72 to 81) in the placebo group.
49 acebo during weeks 1-12), or double-matching placebo group.
50 glucose-lowering medications occurred in the placebo group.
51 olumab group and 6.4 months (3.3-9.6) in the placebo group.
52 the pertuzumab group and 23% (19-28) in the placebo group.
53 the ticagrelor group and 223 patients in the placebo group.
54 ants in the active and 51.7% (76/147) in the placebo group.
55 mg group, and 44 (57%) of 77 patients in the placebo group.
56 ere responders, compared to zero of 6 in the placebo group.
57 group, and three (4%) of 77 patients in the placebo group.
58 compared with 23 of 31 patients (74%) in the placebo group.
59 igned to the SEP-363856 group and 125 to the placebo group.
60 less frequent in the TY014 group than in the placebo group.
61 One patient died by sudden death in the placebo group.
62 ssigned to the golimumab group and 28 to the placebo group.
63 ed to the dexamethasone group and 373 to the placebo group.
64 ants receiving canakinumab compared with the placebo group.
65 gned to the ocrelizumab group and 244 to the placebo group.
66 ib group compared with 63 (89%) of 71 in the placebo group.
67 significantly between the acetaminophen and placebo groups.
68 , and cardiovascular death) in active versus placebo groups.
69 similar in vaccine groups and higher than in placebo groups.
70 re enrolled and randomized 3:1 to TAK-003 or placebo groups.
71 s was low and was similar in the vaccine and placebo groups.
72 Group 1 was the control (placebo) group.
74 ficantly between the golimumab group and the placebo group (0.64+/-0.42 pmol per milliliter vs. 0.43+
75 ard deviation) was -0.6 +/- 6.2 mm Hg in the placebo group, -1.2 +/- 6.8 mm Hg in the potassium nitra
76 n-to-treat population, and 397 (102 [94%] in placebo group, 102 [94%] in 100 mg group, 98 [89%] in 20
78 less after 24 hours in the colchicine versus placebo groups (11% [-14 to 80] versus 66% [1 to 172], P
79 s in the global OLE was higher in the APOLLO-placebo group (13 [27%] of 49), who had a higher disease
80 to the first exacerbation was 67 days in the placebo group, 134 days in the 10-mg brensocatib group,
81 ty between the tranexamic acid groups vs the placebo group (14% vs 17%; difference, -2.9% [95% CI, -7
83 ) was similar in the LY-CoV555 group and the placebo group (19% and 14%, respectively; odds ratio, 1.
84 rivaroxaban group and in 44 patients in the placebo group (2.65% and 1.87%; hazard ratio, 1.43; 95%
86 the UPA group (50.0%) and eight women in the placebo group (21.1%) (a statistically significant diffe
87 28-day mortality between the IFN-beta-1a vs placebo groups (26.4% vs 23.0%; difference, 3.4% [95% CI
88 VL-AUC was lower in the PC786 group than the placebo group (274.1 vs. 406.6 log10PFUe/mL*h, p=0.0359)
89 group (66 [52%] of 127 [43-61]) than in the placebo group (28 [22%] of 126 [15-30]), with percentage
90 erse events were more frequent in the APOLLO-placebo group (28 [57%] of 49) than in the APOLLO-patisi
91 significantly between the peppermint oil and placebo groups: 29 of 62 patients in the small-intestina
92 cantly between the allopurinol group and the placebo group (-3.33 ml per minute per 1.73 m(2) per yea
93 n eczema incidence between the probiotic and placebo groups (35[30%] of 118 infants vs 37[27%] of 137
94 eater in the difelikefalin group than in the placebo group (37.1% [observed data: 64 of 158 patients]
96 erity scores were reductions of 46.0% in the placebo group, 49.0% in the 500 mg group, 55.1% in the 1
97 group, as compared with 100 patients in the placebo group (5.94% and 4.06%; hazard ratio, 1.42; 95%
98 sensitivity in the FMT group compared to the placebo group (+5% +/- 12% in FMT group versus -3% +/- 3
99 lower in the sotagliflozin group than in the placebo group (51.0 vs. 76.3; hazard ratio, 0.67; 95% co
100 etinib group and 1.6 months (1.1-2.7) in the placebo group, 51 patients in the ripretinib group and 3
101 mary endpoint was similar in the vaccine and placebo groups, 53% vs. 45% (RR 1.16, 95% CI .87-1.6, P=
102 he tocilizumab group and 128 patients in the placebo group; 56.0% were Hispanic or Latino, 14.9% were
104 ptom events; 12.9/1000 person-years) and the placebo group (625 depression or clinically relevant dep
106 3) (50 events in 1812 patients analysed) and placebo groups (64 events in 1827 patients; HR 0.78, 0.5
107 reater in the luspatercept group than in the placebo group (70.5% vs. 29.5%), as was the percentage o
108 occurred in 76 (70%) of 108 patients in the placebo group, 70 (65%) of 108 in the 100 mg group, 84 (
109 azidine group (700 [23.3%] patients) and the placebo group (714 [23.7%]; hazard ratio 0.98 [95% CI 0.
110 (13.2), indicating less anxiety, compared to placebo group, - 8.8 (14.7); results did not reach a sig
111 group (159 [64%] of 248 [58-70]) than in the placebo group (81 [33%] of 246 [27-39]) achieved an ACR2
112 gned to the vitamin D group, and 4433 to the placebo group; 95.6% of children had a baseline serum 25
113 djuvanted vaccine group compared with in the placebo group (absolute difference of log(10) ratio of v
114 in the DHA group vs 10.2% of infants in the placebo group (absolute difference, -3.9% [95% CI, -6.8%
115 ing infants in the DHA group vs 31.4% in the placebo group (absolute difference, 11.5% [95% CI, 2.3%
116 oxamine group and in 6 of 72 patients in the placebo group (absolute difference, 8.7% [95% CI, 1.8%-1
117 d with 54.0% and 56.1%, respectively, in the placebo group (adjusted difference in groups, 0.76% [95%
118 he gabapentin group and -0.9 (SD 1.8) in the placebo group (adjusted mean difference -0.18 [97.5% CI
119 he gabapentin group and -1.2 (SD 2.1) in the placebo group (adjusted mean difference -0.20 [97.5% CI
120 tion with crossover patients analysed in the placebo group; analyses were not adjusted for crossover
121 69), 26.1% (18/69), and 27.5% (19/69) in the placebo group and 0%, 0%, 0%, 0%, 0%, and 1.4% (1/72) in
122 confidence interval [CI] = 0.27-0.51) in the placebo group and 0.37 (95% CI = 0.25-0.49) in the HCFD
123 There were 111 blood transfusions in the placebo group and 105 in the intravenous iron group (rat
124 reported in 122 (53%) of 230 patients in the placebo group and 119 (51%) of 232 patients in the galca
126 9 randomly assigned participants (207 in the placebo group and 202 in the maraviroc group) who receiv
128 trial population, 6% of the patients in the placebo group and 3% of the patients in the combined REG
131 o) in serum vitamin D3 was -0.1 ng/mL in the placebo group and 6.8 ng/mL in the 2000 IU/d group (abso
132 At 12 weeks, 24 (57%) of 42 patients in the placebo group and 68 (41%) of the 164 patients in the bi
133 elapse occurred in 40 children (2.2%) in the placebo group and in 58 children (3.1%) in the amoxicill
135 in 300 mg S44819 group, and 50 s [38-68] in placebo group) and B (107 s [81-144] in 150 mg S44819 gr
136 ed injection-site erythema (35% vs 8% in the placebo group) and nasopharyngitis (17% vs 4% in the pla
137 08 to the sotagliflozin group and 614 to the placebo group) and were followed for a median of 9.0 mon
138 isiran group, 38 (78%) of 49 from the APOLLO-placebo group, and 25 (100%) of 25 from the phase 2 OLE
139 nty-seven participants (37 eyes) were in the placebo group, and 26 participants (36 eyes) were in the
140 d, and 206 were randomly assigned: 42 to the placebo group, and 41 each to the four bimekizumab group
141 ents in probiotic group and 78 events in the placebo group, and deaths accounted for 33 of the events
142 reater in the luspatercept group than in the placebo group, and few adverse events led to the discont
143 sotagliflozin group and 5292 assigned to the placebo group, and followed for a median of 16 months.
144 01.4 in the SEP-363856 group and 99.7 in the placebo group, and the mean change at week 4 was -17.2 p
145 ycycline group and 112 patients (90%) in the placebo group; aneurysm repair in 13 (10%) and 9 (7%), a
146 al power, we evaluated this end point in the placebo group as compared with the combined AK002 group.
147 in the zoledronic acid group vs -16.8 in the placebo group; between-group difference, 5.2 [95% CI, -2
149 ients to 1 of 3 praliciguat dose groups or a placebo group, but was refocused early to a comparison o
151 ts, 88% in the Lactin-V group and 84% in the placebo group could be evaluated for the primary outcome
152 causes of death between the azithromycin and placebo groups could be attributable to the broad spectr
154 capivasertib group vs 17 [24%] of 71 in the placebo group), diarrhoea (ten [14%] vs three [4%]), ras
156 group compared with 37 of 73 (50.7%) in the placebo group (difference of proportions, -8.6% [95.48%
157 uction of 1.7 points (change, -20.2%) in the placebo group (difference, -32.8 percentage points; 95%
158 up and in 306 of 339 patients (90.3%) in the placebo group (difference, -6.4 percentage points [95% c
159 CI, 0.30 to 0.41 cm) for 101 patients in the placebo group (difference, 0.0; 95% CI, -0.07 to 0.07 cm
160 in the tranexamic acid groups vs 62% in the placebo group (difference, 3.5%; [90% 1-sided confidence
161 he golimumab group and in 7% of those in the placebo group (difference, 36 percentage points; 95% CI,
162 ot differ between the hydroxychloroquine and placebo groups (difference in symptom severity: relative
163 megranate juice group and 33 subjects in the placebo group dropped out before completing the study.
164 oint in the oxytocin-group compared with the placebo-group (effect size -1.12; -1.53 to -0.70; P < .0
165 e group and in 20 of 105 participants in the placebo group (estimated percentage, 43.3% vs. 18.7%), a
166 orter in the steroid group compared with the placebo group even though both groups included patients
167 oportions of patients in the mepolizumab and placebo groups experienced on-treatment adverse events (
168 increase of 6.2% (95% CI, 3.3 to 9.2) in the placebo group, for a between-group difference of -44.3 p
169 ncrease of 8.2% (95% CI, 4.3 to 12.2) in the placebo group, for a between-group difference of -47.9 p
170 as compared with an increase of 1.9% in the placebo group, for a between-group least-squares mean di
171 .5% in the evolocumab group and -6.2% in the placebo group, for a difference of -38.3 percentage poin
172 g per deciliter (-0.2 mmol per liter) in the placebo group, for a difference of -68.6 mg per decilite
173 convalescent plasma group and 11.43% in the placebo group, for a risk difference of -0.46 percentage
174 thrombin-antithrombin complex levels in the placebo group; for those values exceeding the upper limi
175 tib group versus 4.8 months (3.1-7.7) in the placebo group, giving an unadjusted hazard ratio (HR) of
177 28], and rash [n = 31]) and patients in the placebo group had 640 adverse events (nausea [n = 67], d
179 ne group and 366 (29.7%) participants in the placebo group had achieved continuous abstinence (risk d
182 cipants in the liraglutide group than in the placebo group had gastrointestinal adverse events (81 of
183 tients in the ripretinib group and 37 in the placebo group had had progression-free survival events.
185 ays compared with baseline (13.4), while the placebo group had on average 1.0 fewer than at baseline
186 8 in the carboxymaltose group and 550 in the placebo group) had at least one post-randomisation value
187 tuzumab group and 40.8 months (36-48) in the placebo group (hazard ratio 0.69, 95% CI 0.58-0.82); 8-y
188 ib group versus 8.8 months (8.0-10.3) in the placebo group (hazard ratio [HR] 0.43 [95% CI 0.35-0.53]
189 nd 56.3 months (95% CI, 54.4 to 63.0) in the placebo group (hazard ratio for death, 0.73; 95% CI, 0.6
190 roup and 19.3% (95% CI, 13.3 to 27.4) in the placebo group (hazard ratio for mechanical ventilation o
191 hemoprevention group and 316 occurred in the placebo group (hazard ratio, 0.65; 95% confidence interv
192 eatment group and in 83 (5.8%) in the double-placebo group (hazard ratio, 0.69; 95% CI, 0.50 to 0.97)
193 and 7.5 events per 100 patient-years in the placebo group (hazard ratio, 0.74; 95% confidence interv
194 the polypill group and in 157 (5.5%) in the placebo group (hazard ratio, 0.79; 95% confidence interv
195 n the aspirin group and in 134 (4.7%) in the placebo group (hazard ratio, 0.86; 95% CI, 0.67 to 1.10)
196 p and in 972 of 2524 patients (38.5%) in the placebo group (hazard ratio, 0.90; 95% confidence interv
197 c group and 11.2 per 100 person-years in the placebo group (hazard ratio, 0.97 [95% CI, 0.57 to 1.67]
198 p and in 327 of 2745 patients (11.9%) in the placebo group (hazard ratio, 0.97; 95.6% confidence inte
199 rric carboxymaltose group vs 78 [14%] in the placebo group; hazard ratio [HR] 0.96, 95% CI 0.70-1.32,
201 ic carboxymaltose group and 209 (38%) in the placebo group (HR 0.80, 95% CI 0.66-0.98, p=0.030).
202 03 group compared with 29 (9%) of 316 in the placebo group improved at month 12, with confirmation at
203 higher in the oral insulin group than in the placebo group in each trial (P < 0.05; P = 0.057 when ad
204 etween the convalescent plasma group and the placebo group in the distribution of clinical outcomes a
205 nce between the erythropoietin group and the placebo group in the incidence of death or severe neurod
206 e was no difference between the riluzole and placebo groups in the primary endpoint of change in mJOA
207 fference (combined REGN-COV2 dose groups vs. placebo group) in the time-weighted average change in vi
208 cine group and in 157 patients (5.7%) in the placebo group (incidence, 1.5 vs. 2.1 events per 100 per
209 cine group and in 264 patients (9.6%) in the placebo group (incidence, 2.5 vs. 3.6 events per 100 per
210 nt group, which was more frequently than the placebo group, included nausea, constipation, dizziness,
211 ined AK002 group, as compared with 9% in the placebo group (least-squares mean difference, -98 percen
212 in D group and 10.7 ng per milliliter in the placebo group (mean between-group difference, 20.3 ng pe
213 oved from global OLE enrolment in the APOLLO-placebo group (mean change from global OLE enrolment -1.
214 s in the vitamin D3 group vs 253 days in the placebo group (mean group difference, -13.1 days [95% CI
215 % +/- 12% in FMT group versus -3% +/- 32% in placebo group, mean difference 9%, 95% CI -5% to 28%, p
216 e folic acid and zinc group and 27.2% in the placebo group; mean difference, 2.4% [95% CI, 0.5% to 4.
217 ly differ between the hydroxychloroquine and placebo groups (median [IQR] score, 6 [4-7] vs 6 [4-7];
220 ]), and hypophosphataemia (two (2%]); in the placebo group (n=43), the most common (>2%) grade 3 or 4
224 n 300 mg S44819 group, and 130 s [86-175] in placebo group) of the Trail Making Test, and the Barthel
225 ion: 152 to the Lactin-V group and 76 to the placebo group; of these participants, 88% in the Lactin-
226 etween each of the two S44819 groups and the placebo group (OR 0.91 [95% CI 0.64-1.31]; p=0.80 for 15
227 nt between the zoledronic acid group and the placebo group over 24 months (-878 mm3 vs -919 mm3; betw
229 ission compared with 4.4% of patients in the placebo group (P < .001 for both comparisons of BOT with
230 es from all SER-287 groups compared with the placebo group (P < .05), but this difference was not mai
231 the PVP-I/DEX group vs 42.8% (95/222) in the placebo group (P = .127), and bacterial eradication was
232 -6.6) minutes per hour among patients in the placebo group (P = .29), with an estimated median differ
233 uat group and in 7.9% of the patients in the placebo group (P = 0.12), and syncope occurred in 4.0% o
242 umab group vs 36 [8%] of 437 patients in the placebo group), peripheral neuropathy (25 [6%] vs 12 [3%
243 (72.5 per 100 patient-years) occurred in the placebo group (rate ratio [RR] 0.79, 95% CI 0.62-1.01, p
244 S44819 group, and 191 (99%) patients in the placebo group received at least one dose of treatment an
245 S44819 group, and 193 (100%) patients in the placebo group received at least one dose of treatment, a
247 the vitamin D(3) group and two events in the placebo group; relative risk 1.25, 95% CI 0.43-3.66; Fis
248 up and 46 (3.7%) of 1233 participants in the placebo group reported serious adverse events (94 events
249 and 1.77% of patients in the rivaroxaban and placebo groups, respectively (hazard ratio: 0.72; 95% co
250 and 0.18% of patients in the rivaroxaban and placebo groups, respectively (hazard ratio: 1.44; 95% co
252 nd 74% (CI, 63% to 88%) in the rituximab and placebo groups, respectively, an absolute difference of
255 lic acid and zinc group and 416 [35%] in the placebo group; risk difference, -0.9% [95% CI, -4.7% to
256 carboxymaltose group and 294 occurred in the placebo group (RR 0.74; 95% CI 0.58-0.94, p=0.013).
257 carboxymaltose group and 451 occurred in the placebo group (RR 0.80, 95% CI 0.64-1.00, p=0.050).
258 elated deaths occurred in one patient in the placebo group (septic shock and pulmonary oedema) and on
259 was not significant (ES = 0.15), whereas the placebo group showed a significant decline (ES = -0.35).
260 supplementation group and 4.0 +/- 2.2 in the placebo group, showing no group difference (p = 0.819).
262 mab group versus 7.9 months (7.0-9.3) in the placebo group (stratified HR 0.887 [95% CI 0.724-1.086];
263 ariables in the 98 pomegranate juice and 102 placebo group subjects who completed the study did not d
264 mary endpoints at week 12, compared with the placebo group, the proportion of patients who had achiev
265 p, as did 495.2 per 100 patient-years in the placebo group; the incidence of serious adverse events a
266 s in the rivaroxaban group and in 584 in the placebo group; the Kaplan-Meier estimates of the inciden
267 he 10-mg/d vericiguat group, and 3.4% in the placebo group; those with syncope were 1.5%, 0.8%, and 0
268 300 mg S44819 group, and 22.0 [17.0-26.0] in placebo group), time needed to complete parts A (50 s [I
269 ived; crossover patients were counted in the placebo group up to the day before first pertuzumab dose
270 n the tocilizumab group as compared with the placebo group was 0.83 (95% confidence interval [CI], 0.
271 category in the LY-CoV555 group than in the placebo group was 0.85 (95% confidence interval [CI], 0.
272 between patients in the vosoritide group and placebo group was 1.57 cm/year in favour of vosoritide (
273 ntration between the tofersen groups and the placebo group was 2 percentage points (95% confidence in
274 e to the first adjudicated recurrence in the placebo group was 8.6 weeks (95% confidence interval [CI
276 ath in the chemoprevention group than in the placebo group was restricted to the intervention period
277 .47) and between the 10-mg/d vericiguat and placebo groups was -0.5 (95% CI, -4.6 to 3.5; P = .80).
278 in scores between the 15-mg/d vericiguat and placebo groups was -1.5 (95% CI, -5.5 to 2.5; P = .47) a
279 ; 21 events out of 4533 patients) and across placebo groups was 0.47% (0.26-0.85; I(2)=0%, chi(2) p=1
280 baseline to week 8 in the 1500 mg IW-3718 vs placebo groups was a reduction of 17.5% (95% confidence
281 e tocilizumab group and 8.6% of those in the placebo group (weighted difference, 2.0 percentage point
282 g per kilogram and 5 mg per kilogram and the placebo group were -50.5 percentage points (P<0.001) and
283 mg weekly, and 300 mg every 2 weeks and the placebo group were -56.0, -52.9, and -38.5 percentage po
284 mycin group and 1735 (91.9%) children in the placebo group were ascertained by verbal autopsy intervi
285 ) in the LY-CoV555 group and 81 (54%) in the placebo group were in one of the two most favorable cate
286 he eplerenone group and 54 patients from the placebo group were included in the primary outcome.
287 thromycin group and 1888 child deaths in the placebo group were reported from the population censuses
288 zumab group and 21.2% of the patients in the placebo group were still receiving supplemental oxygen.
290 cipants randomized to the co-trimoxazole and placebo groups were 0.45 (84/186) and 0.38 (80/209), res
291 15-mg/d vericiguat, 10-mg/d vericiguat, and placebo groups were 295.0 m and 311.8m , 292.1 m and 318
292 15-mg/d vericiguat, 10-mg/d vericiguat, and placebo groups were 60.0 and 68.3, 57.3 and 69.0, and 59
293 g the intervention phase between aspirin and placebo groups were similar, and no significant differen
295 s in the cytisine group and 90 events in the placebo group), which included 91 deaths (49 in the cyti
296 sivir and 79 to placebo); one patient in the placebo group who withdrew after randomisation was not i
297 tter in the melatonin group than that in the placebo group with a mean (SD) of 69.7 (21.2) and 60.7 (
298 ients [12%]) versus 14 patients (30%) in the placebo group (with 6 infectious serious adverse events
299 enetoclax group and 48 (50%) patients in the placebo group, with eight (4%) treatment-emergent fatal
300 mavacamten group versus a 4% increase in the placebo group, with geometric mean differences of -0.008